Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More
Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme's ENHANZE drug delivery ... Read More
Corium, Lotus Pharmaceutical seal deal for Alzheimer’s drug ADLARITY in Asia
Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers ... Read More
Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More
Quanterix launches diagnostic test aiding early Alzheimer’s detection
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed to aid in the evaluation of patients ... Read More
Roche, Lilly team up to develop EAPP blood test for Alzheimer’s disease
Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid Plasma Panel (EAPP) blood test which has ... Read More
Eisai, Biogen secure Leqembi FDA accelerated approval for Alzheimer’s disease
Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly developed Leqembi (lecanemab-irmb) under the accelerated approval ... Read More
Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer's type by randomizing the first patient. According ... Read More
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More
PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer's disease ... Read More